Elanco Animal Health Incorporated $ELAN Shares Sold by Teza Capital Management LLC

Key Points

• Teza Capital Management LLC significantly decreased its stake in Elanco Animal Health by selling 86,911 shares, reducing its holdings by 87.1% to just 12,907 shares.
• Elanco Animal Health recently reported earnings of $0.26 per share, exceeding estimates and showing a revenue growth of 4.8% compared to the previous year.
• Research firms have varied opinions on Elanco, with Wall Street Zen upgrading it to a "buy" while Zacks Research downgraded it to a "hold."

Teza Capital Management LLC lessened its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 87.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,907 shares of the company's stock after selling 86,911 shares during the period. Teza Capital Management LLC's holdings in Elanco Animal Health were worth $136,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Allworth Financial LP grew its holdings in Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after acquiring an additional 2,090 shares in the last quarter. CoreCap Advisors LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at $29,000. NBC Securities Inc. acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at $40,000. Parallel Advisors LLC boosted its holdings in shares of Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after buying an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc boosted its holdings in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after buying an additional 1,740 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Price Performance

Shares of ELAN traded up $0.04 during trading hours on Monday, reaching $18.57. The company had a trading volume of 1,164,143 shares, compared to its average volume of 5,977,678. The firm has a 50 day simple moving average of $16.37 and a 200-day simple moving average of $13.21. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $9.23 billion, a price-to-earnings ratio of 21.60, a PEG ratio of 3.44 and a beta of 1.62. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $19.08.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business's revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Zacks Research cut shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a report on Thursday, July 17th. Finally, Stifel Nicolaus upped their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, Elanco Animal Health has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.